Phase III Data for C-Cure Cell Therapy Product Candidate Expected in H2 2016;Report Available here: www.lifescicapital.com/equity-research/celyad/
NEW YORK, NY / CRWEPRESSRELEASE / July 31, 2015 /LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Celyad (NasdaqGM: CYAD), a biotherapeutics company developing cell therapies for the treatment of ischemic heart failure and cancer. Celyad is using the Cardiopoiesis platform technology to generate cardiac progenitor cells to repair tissue damage associated with cardiovascular disease. The cells are engineered, bone marrow derived mesenchymal stem cells (MSCs) that are injected directly into the heart, where they accumulate near the site of damage. The Company’s lead product candidate C-cure is currently in a Phase III trial in Europe, with a full data readout expected in the second half of 2016.
Celyad’s recently in-licensed chimeric antigen receptor T cell (CAR-T) platform utilizes chimeric natural killer (NK-cell) receptors to recognize and eliminate tumor cells. This clever variation on CAR technology has many potential advantages including the ability to target multiple cancer types with a single cell therapy. CAR-NKG2D is Celyad’s lead oncology product candidate that is currently in a Phase I trial for acute myeloid leukemia (AML) and multiple myeloma (MM). Data from the trial are expected in the second half of 2016.
In a 43 page Initiation Report LifeSci Capital explains the scientific foundation of Celyad’s cell therapy programs, provides details of completed and ongoing clinical trials, and examines the potential market opportunities for the Company’s product candidates.
Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Celyad as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
SOURCE:LifeSci Capital, LLC